Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial

Adlai Nortye (ANL) partnered with Lilly (LLY) and Merck KGaA for a trial of its cancer drug AN4035. Lilly and Merck will supply cetuximab for free in the US, Australia, and China. AN4035 targets colorectal, pancreatic, and lung cancers. ANL's stock is down 25.96% over 20 days, closing at $11.61 on the announcement day.

Original reporting
Published Oct 15, 2026, 11:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial — source image
Decision brief

The 30-second read

$ANLNeutralMed
01

Why it matters

The collaboration validates AN4035's mechanism but immediate price reaction was muted; investors may watch short‑interest dynamics and upcoming trial data.

02

Market read

Primary biotech news with modest immediate impact; relevance for traders lies in monitoring trial outcomes and short‑interest pressure.

03

What to watch

Future data from the AN4035 trial and upcoming AN9025 readout could drive significant re‑rating.

Relevance 7/10Novelty 8/10Timing: same-day release

Background

Adlai Nortye (ANL) announced a clinical trial partnership with Eli Lilly (LLY) and Merck KGaA, supplying cetuximab for its AN4035 ADC candidate.

Company-level read

Ticker impact

$ANLNeutralMedium confidence
Context

Adlai Nortye disclosed a new clinical trial collaboration and supply agreement with Eli Lilly and Merck KGaA for its experimental cancer drug AN4035.

Expected impact

slight upside pressure as investors assess trial potential

Evidence & confidence

Trial collaboration is material for a biotech micro‑cap, yet short interest remains high and price reaction was muted.

$LLYNeutralHigh confidence
Context

Eli Lilly will supply cetuximab at no cost for the AN4035 trial, marking its involvement in the collaboration.

Expected impact

no material impact on LLY price

Evidence & confidence

Supply agreement is a small, non‑financial contribution to a partner's trial.

Market effects

Adds a new RAS‑targeting trial to the biotech pipeline, modestly supporting the oncology sector.

US biotech investors may note the trial expansion to Australia and China.

Limited to niche biotech investors; no broad market effect.

Counterpoint

High short interest suggests the market may be underpricing potential upside if trial data prove positive.

Key entities

  • Adlai Nortye Group Ltd

    Biotech firm developing AN4035

  • Eli Lilly and Company

    Supplies cetuximab for the trial

  • Merck KGaA

    Supplies cetuximab for sites in Australia and China

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$LLYMed

Health Canada approves Eli Lilly’s GLP-1 pill for weight loss

Health Canada approved Eli Lilly's GLP-1 pill, Foundayo, for weight loss and Type 2 diabetes. The daily pill targets adults with obesity or overweight with related conditions. Eli Lilly expects pharmacy availability in January. Foundayo competes with Novo Nordisk's injectables and Rybelsus, a GLP-1 pill for diabetes only. The active ingredient, orforglipron, is a non-peptide GLP-1 receptor agonist.

$MRKMed

Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

Merck (MRK) is discontinuing development of nemtabrutinib, an experimental BTK inhibitor acquired via its $2.7B purchase of ArQule, due to safety concerns identified in late-stage trials. The decision follows recommendations from a data monitoring committee and Merck's own review, leading to the halt of several Phase 3 studies in the BELLWAVE program. The drug was being evaluated for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.